BERNARDSVILLE, N.J., Oct. 03, 2019 (GLOBE NEWSWIRE) -- Anima Biotech, the leader in the discovery of drugs that control mRNA translation, today announced the company will present at BioJapan 2019 taking place in Yokohama, Japan, October 9 – 11, 2019.

Kevin Pong, Ph.D., Vice President of Business Development of Anima Biotech, will provide an overview of the company’s Translation Control Therapeutics technology for the discovery of small molecule drugs that control mRNA translation. He will be available for questions and one-on-one meetings with attendees registered for the conference.

Details regarding the company’s presentation are as follows:

Event: BioJapan 2019
Date: Thursday, October 10, 2019
Time: 10:40 – 10:55 a.m. JST
Location: Exhibitor's Stage l
Venue: Pacifico Yokohama National Convention Hall, Yokohama, Japan

About Anima Biotech

Anima Biotech is advancing Translation Control Therapeutics, the first and only platform for the discovery of small molecule drugs that control mRNA translation as a new strategy against many diseases. With novel biology that monitors the translation of proteins and proprietary cloud-based analysis software, we identify drug candidates that modulate a target protein’s production. We develop a pipeline across therapeutic areas and partner with Pharma for their targets including our $1B+ collaboration with Lilly for the discovery and development of translation inhibitors of several targets. Our approach was further validated with 5 granted patents, 14 peer reviewed publications and 17 scientific collaborations. To learn more about us, visit https://www.animabiotech.com

Media Contact:
Andrew Mielach
LifeSci Public Relations
+1.646.876.5868
amielach@lifescipublicrelations.com 

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.